鶹ý

New Evidence Sheds Light on Muhammad Ali's Parkinson's Disease

— Was boxing to blame?

MedpageToday
A photo of Muhammad Ali

Muhammad Ali had idiopathic Parkinson's disease that emerged at an early age, according to new evidence from physicians who repeatedly evaluated the fighter over 20 years.

"Based on extensive long-term clinical and cinematic follow-up, it is clear that Muhammad Ali had young-onset tremor-dominant idiopathic Parkinson's disease," reported Michael Okun, MD, of the University of Florida in Gainesville, and co-authors.

The pattern of Ali's symptoms showed his disease was prolonged, progressive, and responsive to dopamine, the group wrote in a viewpoint published in .

"This viewpoint represents the first time that a group of physicians who continuously evaluated him over the years has, with permission from the family, spoken on the record," Okun told 鶹ý. "Ali is a vitally important part of our history and it is important we accurately document his Parkinson's disease symptoms and his disease course."

"There remains a substantial amount of uncertainty in the degree to which Parkinson's disease versus repeated hits to the head contributed to Muhammad Ali's progressive tremor and cognitive impairment," he said.

"Thirty-plus years of a progressive, asymmetric, dopamine-responsive resting tremor, accompanied by other classical features, provides strong evidence for a diagnosis of idiopathic Parkinson's disease in Ali," Okun noted. "Post-traumatic syndromes with tremor have a different presentation."

Ali's symptoms were clear in a that showed him lighting the 1996 Olympic torch, Okun and co-authors pointed out. "Ali manifested a classic Parkinson's disease left-arm rest tremor, which was suppressed as he raised his left hand to steady his right arm in order to light the torch," they wrote.

In the late 1970s, Ali's family members noted slowness, Okun and colleagues said. From 1981 to 1984, he had a series of single medical examinations at the University of California Los Angeles, the Mayo Clinic in Rochester, Minnesota, and Columbia-Presbyterian in New York City, which raised possible diagnoses of both head trauma and Parkinson's disease or a parkinsonian syndrome.

From 1995 until his death in 2016, Ali received his neurological care largely at Emory University in Atlanta. Okun and co-authors presented information from 20 years of clinical reports when Ali had in-person visits, testing, and hospitalizations at Emory.

"Muhammad Ali's disease course, from his late 30s until his death at age 74 years, was chronic and progressive," they wrote. "He manifested fatigue, hypophonia, bradykinesia, and a masked face, as well as many of the visible motor symptoms of Parkinson's disease. He was clearly responsive to levodopa, as documented in his several examinations in the early 1980s, a feature usually not present following traumatic brain injury."

Ali's fluorodeoxyglucose (FDG) PET scan at Emory in 1997 showed progressive bilateral striatal hyperactivity, Okun and co-authors reported. A fluorodopa F 18 PET scan in 1998 showed classic low striatal uptake. "Like the FDG PET, this study was consistent with Parkinson's disease and not traumatic brain injury," the authors wrote.

Dopamine transporter scanning to differentiate parkinsonism from essential tremor was not available at the time. MRI revealed brainstem atrophy, third ventricular enlargement, and a cavum septum pellucidum.

"Over the course of many years, Ali's face became gradually more masked, his speech more hypophonic, and he developed the classic late-stage symptoms of idiopathic Parkinson's disease, including a stooped posture, shuffling steps, postural instability, and falling," Okun and colleagues observed.

Polysomnography confirmed Ali had rapid-eye movement sleep behavioral disorder. His weight slowly declined. Serial neuropsychological testing showed progressive frontal and memory impairments.

"He had mild occasional depression," the physicians wrote. "Ali remained generally positive and embraced his diagnosis, despite the realization it was chronic and progressive."

Ali died of sepsis on June 3, 2016. Though his medical team discussed autopsy with him, Ali declined for religious reasons.

"Given the lack of a final tissue diagnosis, we rely on the detailed clinical follow-up and serial PET imaging studies to understand Ali's medical condition. A 34-year chronic progressive presentation with asymmetric levodopa-responsive resting tremor, accompanied by other classical features, provides strong evidence for a diagnosis of idiopathic Parkinson disease," Okun and colleagues stated.

"In contrast, post-traumatic tremor is commonly transitory, and manifests as a postural and/or kinetic tremor," they continued. "In addition, post-traumatic tremor is not accompanied by progressive cogwheel rigidity and bradykinesia, both observed in Ali."

Head trauma is a known risk factor for later onset of Parkinson's disease, the authors acknowledged. "However, a causative association in the Ali case cannot be determined," they wrote.

  • Judy George covers neurology and neuroscience news for 鶹ý, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more.

Disclosures

Okun reported grants from the NIH, Michael J. Fox Foundation, Parkinson Alliance, Smallwood Foundation, Bachmann-Strauss Foundation, University-Florida Foundation, and Tourette Association of America; fees from the Parkinson's Foundation for being a medical advisor; and royalties for publications. He is an associate editor for the New England Journal of Medicine Journal Watch Neurology and has been an investigator for NIH, foundation, and industry-sponsored trials.

Co-authors reported relationships with NIH, Wellcome Leap, Hope for Depression Research Foundation, Klingenstein Foundation, Blackrock Neurotech, Cogwear, and Abbott Labs.

Primary Source

JAMA Neurology

Okun MS, et al "Muhammad Ali and young-onset idiopathic Parkinson disease -- the missing evidence" JAMA Neurol 2022; DOI: 10.1001/jamaneurol.2022.3584.